Specialty pharmacies reduce administrative burden and total cost of care as advanced therapies move to community sites, Fran ...
Pirtobrutinib plus venetoclax-rituximab reduced progression/death risk versus venetoclax-rituximab alone in R/R CLL/SLL, with higher undetectable MRD rates at 10–6. Head-to-head FLT3 inhibition in ...
For Europe to remain an attractive site for phase 3 research, he argued, regulatory predictability is paramount. El-Galaly ...
Shannon L. Maude, MD, PhD, highlighted promising long-term disease-free survival and MRD negativity with tisagenleucel in ...
To mitigate this risk, the Chaparro recommends pairing pharmacologic therapy with light resistance or weight training and ...
In the final episode, 'From Specialist Roles to Unmet Needs: Advancing Alopecia Areata Care,' the panelists explored the ...
Welcome back to another AJMC Insights series. In this episode titled, 'Setting the Stage: Treatment Selection and Eligibility ...
Lin: Genomic classifiers are widely used to assess the risk of distant metastasis (DM) and inform chemotherapy (CT) decisions ...
Re-engagement strategies for hepatitis B show promise in the US, but data gaps and structural barriers are slowing progress ...
State data reveal 2026 ACA marketplace enrollment losses are accelerating post open enrollment, as cancellations surge and ...
In this interview with the American Journal of Managed Care ® (AJMC ®), Iain MacPherson, professor of breast oncology at ...
The 2026 EHA Congress, convening in Stockholm next week, will bring the global hematology community together for 4 days of science, debate, and discovery. Highlights from EHA 2025 included use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results